User:Leroyjoenoes/Vaccinology/Bibliography

Bibliography

As you gather the sources for your Wikipedia contribution, think about the following:

Is the source from a reliable publication?
- Reliable publications include established newspapers, academic journals and books, textbooks, and other published sources with reputations for accuracy and fact-checking.
- Unreliable sources include blog posts and other self-published works, press releases, and social media posts.
Is the source verifiable?
- In order for a source to be considered verifiable, other editors should be able to consult the source.
Is the source independent of the subject?
- Is the source connected in any way to the subject? This is especially important when writing biographies or about organizations.
- For example, if you were writing a biography, sources like the person's webpage or personal blog would not be considered independent.
Is the source primary or secondary?
- Primary sources include first-hand accounts, autobiographies, and other original content.
- Wikipedia allows limited use of primary sources, but typically only for straightforward, descriptive statements of facts, and only if they are published and verifiable without requiring specialized knowledge.
- Secondary sources should be the main basis for a biography on Wikipedia.
If you're working on a topic related to medicine or psychology, ensure that your sources follow these special guidelines.
If you're creating a new article, consider the following:
- Ensure that your topic meets Wikipedia's notability guidelines.
- In order for a topic to meet the notability requirement, you must be able to identify 2-3 sources that are reliable, verifiable, and independent of the subject you're writing about.
- Finding sufficient sources to establish notability can be especially hard when writing about people or organizations.
- Sources that are not independent of the subject might be useful additions, but don't count towards the notability requirement.
- Wikipedia has developed special guidelines for writing about living persons. Please follow these carefully.
- Wikipedia has a series of guidelines for writing about different categories of people, such as academics and artists. If you're trying to create a new entry about a living person, please look at these carefully.

If you're not sure whether a source is reliable, ask a librarian! If you have questions about Wikipedia's sourcing rules, you can use the Get Help button below to contact your Wikipedia Expert.

Get Help

Bibbliography

1. 1. Barrett, A. D. T. (2016, July 28). Vaccinology in the twenty-first century. Nature News. Retrieved November 8, 2021, from https://www.nature.com/articles/npjvaccines20169#Sec5.
  2. ^ Jump up to:^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o ^p ^q ^r ^s Pollard, A. J., & Bijker, E. M. (2020, December 22). A guide to vaccinology: From basic principles to new developments. Nature News. Retrieved November 8, 2021, from https://www.nature.com/articles/s41577-020-00479-7#Sec3.
  3. ^ Jump up to:^a ^b Bekker, L. G. et al. The complex challenges of HIV vaccine development require renewed and expanded global commitment. Lancet 395, 384–388 (2020).
  4. ^ Jump up to:^a ^b Matz, K. M., Marzi, A. & Feldmann, H. Ebola vaccine trials: progress in vaccine safety and immunogenicity. Expert Rev. Vaccines 18, 1229–1242 (2019).
  5. ^ Jump up to:^a ^b Ahmed, S. F., Quadeer, A. A. & McKay, M. R. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 12, 254 (2020).
  6. ^ Jump up to:^a ^b Pawelec, G. Age and immunity: what is “immunosenescence”? Exp. Gerontol. 105, 4–9 (2018).
  7. ^ Timens, W., Boes, A., Rozeboom-Uiterwijk, T. & Poppema, S. Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response. J. Immunol. 143, 3200–3206 (1989).
  8. ^ Jump up to:^a ^b Plans-Rubio, P. The vaccination coverage required to establish herd immunity against influenza viruses. Prev. Med. 55, 72–77 (2012).
  9. ^ Jump up to:^a ^b Trotter, C. L. & Maiden, M. C. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert. Rev. Vaccines 8, 851–861 (2009)
  10. ^ Larson, H. J. The state of vaccine confidence. Lancet 392, 2244–2246 (2018)
  11. ^ Mitkus, R. J., Hess, M. A. & Schwartz, S. L. Pharmacokinetic modeling as an approach to assessing the safety of residual formaldehyde in infant vaccines. Vaccine 31, 2738–2743 (2013)
  12. ^ Eldred, B. E., Dean, A. J., McGuire, T. M. & Nash, A. L. Vaccine components and constituents: responding to consumer concerns. Med. J. Aust. 184, 170–175 (2006)
  13. ^ Wara, D. W. Host defense against Streptococcus pneumoniae: the role of the spleen. Rev. Infect. Dis. 3, 299–309 (1981).
  14. ^ Patel, M. & Lee, C. K. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Cochrane Database Syst. Rev. 3, CD001093 (2005).
  15. ^ Sandmann, F. et al. Infant hospitalisations and fatalities averted by the maternal pertussis vaccination programme in England, 2012–2017: post-implementation economic evaluation. Clin. Infect. Dis. 71, 1984–1987 (2020).
  16. ^ Demicheli, V., Barale, A. & Rivetti, A. Vaccines for women for preventing neonatal tetanus. Cochrane Database Syst. Rev. 7, CD002959 (2015)
  17. ^ Madhi, S. A. et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N. Engl. J. Med. 383, 426–439 (2020).
  18. ^ Young, M. K. & Cripps, A. W. Passive immunization for the public health control of communicable diseases: current status in four high-income countries and where to next. Hum. Vaccin. Immunother. 9, 1885–1893 (2013).
  19. ^ Moberley, S., Holden, J., Tatham, D. P. & Andrews, R. M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev. 1, CD000422 (2013)
  20. ^ Andrews, N. J. et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect. Dis. 14, 839–846 (2014)
  21. ^ Pollard, A. J., Perrett, K. P. & Beverley, P. C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 9, 213–220 (2009).
  22. ^ Kourtis, A. P., Read, J. S. & Jamieson, D. J. Pregnancy and infection. N. Engl. J. Med. 370, 2211–2218 (2014).
  23. ^ Malley, R. et al. CD4+ T cells mediate antibodyindependent acquired immunity to pneumococcal colonization. Proc. Natl Acad. Sci. USA 102, 4848–4853 (2005).
  24. ^ World Health Organization. Tetanus vaccines: WHO position paper, February 2017 — recommendations. Vaccine 36, 3573–3575 (2018).
  25. ^ World Health Organization. Diphtheria vaccine: WHO position paper, August 2017 — recommendations. Vaccine 36, 199–201 (2018).
  26. ^ Henry, B. & Baclic, O. & National Advisory Committee on Immunization (NACI). Summary of the NACI update on the recommended use of hepatitis B vaccine. Can. Commun. Dis. Rep. 43, 104–106 (2017).
  27. ^ McVernon, J., Johnson, P. D., Pollard, A. J., Slack, M. P. & Moxon, E. R. Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure. Arch. Dis. Child. 88, 379–383 (2003).
  28. ^ McVernon, J. et al. Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years. Pediatr. Infect. Dis. J. 22, 659–661 (2003).
  29. ^ Paunio, M. et al. Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccine. J. Epidemiol. Community Health 53, 173–178 (1999).
  30. ^ Statista Research Department. Herd immunity threshold for selected global diseases as of 2013. Statista https://www.statista.com/statistics/348750/+threshold-for-herd-immunity-for-select-diseases/+(2013).
  31. ^ Plans-Rubio, P. The vaccination coverage required to establish herd immunity against influenza viruses. Prev. Med. 55, 72–77 (2012).
  32. ^ Tabrizi, S. N. et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect. Dis. 14, 958–966 (2014).
  33. ^ Brisson, M. et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic m
  34. ^ Trunz, B. B., Fine, P. & Dye, C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367, 1173–1180 (2006)
  35. ^ Barker, L. & Hussey, G. The Immunological Basis for Immunization Series: Module 5: Tuberculosis (World Health Organization, 2011)
  36. ^ Pollard, A. J., Finn, A. & Curtis, N. Non-specific effects of vaccines: plausible and potentially important, but implications uncertain. Arch. Dis. Child. 102, 1077–1081 (2017).
  37. ^ Mina, M. J., Metcalf, C. J., de Swart, R. L., Osterhaus, A. D. & Grenfell, B. T. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science 348, 694–699 (2015).
  38. ^ Farrington, P. et al. A new method for active surveillance of adverse events from diphtheria/ tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 345, 567–569 (1995).
  39. ^ Nohynek, H. et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 7, e33536 (2012).
  40. ^ Miller, E. et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 346, f794 (2013).
  41. ^ Pinto, M. V., Bihari, S. & Snape, M. D. Immunisation of the immunocompromised child. J. Infect. 72 (Suppl), S13–S22 (2016).
  42. ^ Seligman, S. J. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine 32, 5769–5775 (2014).
  43. ^ Gellin, B. G., Maibach, E. W. & Marcuse, E. K. Do parents understand immunizations? A national telephone survey. Pediatrics 106, 1097–1102 (2000).
  44. ^ Offit, P. A. et al. Addressing parents’ concerns: do multiple vaccines overwhelm or weaken the infant’s immune system? Pediatrics 109, 124–129 (2002).
  45. ^ Peck, M. et al. Global routine vaccination coverage, 2018. MMWR Morb. Mortal. Wkly. Rep. 68, 937–942 (2019).
  46. ^ World Health Organization. Immunization coverage. WHO https://www.who.int/news-room/fact-sheets/+detail/immunization-coverage+(2020).
  47. ^ World Health Organization. More than 9.4 million children vaccinated against typhoid fever in Sindh. WHO http://www.emro.who.int/pak/pakistan-news/+more-than-94-children-vaccinated-with-typhoidconjugate-vaccine-in-sindh.html+(2019).
  48. ^ Jump up to:^a ^b World Health Organization. Disease outbreaks. WHO https://www.who.int/emergencies/diseases/en/ (2020).
  49. ^ Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220 (2009).
  50. ^ Fauci, A. S., Marovich, M. A., Dieffenbach, C. W., Hunter, E. & Buchbinder, S. P. Immunology. Immune activation with HIV vaccines. Science 344, 49–51 (2014).
  51. ^ Agnandji, S. T. et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367, 2284–2295 (2012).
  52. ^ Inoue, N., Abe, M., Kobayashi, R. & Yamada, S. Vaccine development for cytomegalovirus. Adv. Exp. Med. Biol. 1045, 271–296 (2018).
  53. ^ Schleiss, M. R., Permar, S. R. & Plotkin, S. A. Progress toward development of a vaccine against congenital cytomegalovirus infection. Clin. Vaccine Immunol. 24, e00268–e00317 (2017).
  54. ^ Koff, W. C. & Schenkelberg, T. The future of vaccine development. Vaccine 38, 4485–4486 (2020).
  55. ^ van Riel, D. & de Wit, E. Next-generation vaccine platforms for COVID-19. Nat. Mater. 19, 810–812 (2020).
  56. ^ Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2034577 (2020).
  57. ^ Zhang, C., Maruggi, G., Shan, H. & Li, J. Advances in mRNA vaccines for infectious diseases. Front. Immunol. 10, 594 (2019).
  58. ^ Mascola, J. R. & Fauci, A. S. Novel vaccine technologies for the 21st century. Nat. Rev. Immunol. 20, 87–88 (2020)
  59. ^ Peyraud, N. et al. Potential use of microarray patches for vaccine delivery in low- and middle-income countries. Vaccine 37, 4427–4434 (2019)